Business Description
Fresenius SE & Co KGaA
ISIN : DE0005785604
Share Class Description:
XSWX:FRE: Ordinary SharesTotal Employee Number:
177,783Compare
Compare
Traded in other countries / regions
FRE.Germany0OO9.UKFSNUY.USAFRE.Austria1FRE.ItalyFRE.SwitzerlandFREN.Mexico IPO Date
2014-11-03Description
Fresenius is a healthcare holding company based in Germany. The company owns a minority stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals primarily in Germany and Spain.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.33 | |||||
Equity-to-Asset | 0.47 | |||||
Debt-to-Equity | 0.6 | |||||
Debt-to-EBITDA | 3.24 | |||||
Interest Coverage | 7.38 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 1.42 | |||||
Beneish M-Score | -2.84 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1.9 | |||||
3-Year EBITDA Growth Rate | 6.5 | |||||
3-Year EPS without NRI Growth Rate | -7 | |||||
3-Year FCF Growth Rate | -29.1 | |||||
3-Year Book Growth Rate | -2.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 5.77 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 4.55 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 94.7 | |||||
9-Day RSI | 78.23 | |||||
14-Day RSI | 62.04 | |||||
3-1 Month Momentum % | -10.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.27 | |||||
Quick Ratio | 0.98 | |||||
Cash Ratio | 0.41 | |||||
Days Inventory | 55.71 | |||||
Days Sales Outstanding | 59.95 | |||||
Days Payable | 26.85 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 2.68 | |||||
3-Year Dividend Growth Rate | 2.8 | |||||
Forward Dividend Yield % | 2.68 | |||||
5-Year Yield-on-Cost % | 2.68 | |||||
Shareholder Yield % | 6.92 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 25.24 | |||||
Operating Margin % | 9.1 | |||||
Net Margin % | 6.38 | |||||
EBITDA Margin % | 15.96 | |||||
FCF Margin % | 6.17 | |||||
OCF Margin % | 12.65 | |||||
ROE % | 7.72 | |||||
ROA % | 3.49 | |||||
ROIC % | 3.99 | |||||
3-Year ROIIC % | -0.67 | |||||
ROC (Joel Greenblatt) % | 22.95 | |||||
ROCE % | 7.64 | |||||
Years of Profitability over Past 10-Year | 9 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 15.35 | |||||
Forward PE Ratio | 10.81 | |||||
PE Ratio without NRI | 12.39 | |||||
Shiller PE Ratio | 11.31 | |||||
Price-to-Owner-Earnings | 12.47 | |||||
PS Ratio | 0.97 | |||||
PB Ratio | 1.14 | |||||
Price-to-Tangible-Book | 7.44 | |||||
Price-to-Free-Cash-Flow | 15.82 | |||||
Price-to-Operating-Cash-Flow | 7.71 | |||||
EV-to-EBIT | 12.21 | |||||
EV-to-Forward-EBIT | 11.25 | |||||
EV-to-EBITDA | 8.46 | |||||
EV-to-Forward-EBITDA | 7.9 | |||||
EV-to-Revenue | 1.35 | |||||
EV-to-Forward-Revenue | 1.29 | |||||
EV-to-FCF | 21.96 | |||||
Price-to-GF-Value | 1.09 | |||||
Price-to-Projected-FCF | 0.6 | |||||
Price-to-Median-PS-Value | 1.25 | |||||
Price-to-Graham-Number | 2.02 | |||||
Earnings Yield (Greenblatt) % | 8.19 | |||||
FCF Yield % | 6.31 | |||||
Forward Rate of Return (Yacktman) % | -6.73 |
Fresenius SE & Co KGaA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Fresenius SE & Co KGaA Stock Events
| Event | Date | Price (CHF) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-04 | In 133 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 133 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 | In 42 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 42 days | ||
| EUR 1.050000 Cash Dividend | 2026-05-26 | 36.20 (+0.00%) | ||
| General meeting for 2026 | 2026-05-22 | 36.20 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-06 13:30 | 38.26 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 38.26 (+0.00%) | ||
| Annual report for 2025 | 2026-03-25 | 40.61 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-25 13:30 | 46.36 (+0.00%) |
Show
Entries
Press Release
| Subject | Date | ||
|---|---|---|---|
| Fresenius SE & Co. KGaA to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on 13 November 2019 | 2019-11-06 |
Articles on Fresenius SE & Co KGaA
No articles.